ICM
IOVA icon

Invenomic Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Invenomic Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17M Sell
1,482,595
-7,012,956
-83% -$26.6M 0.37% 76
2026
Q1 		$29.8M Sell
8,495,551
-3,463,954
-29% -$11.1M 1.37% 24
2025
Q4 		$32.6M Buy
11,959,505
+1,417,897
+13% +$3.28M 1.52% 18
2025
Q3 		$22.9M Buy
10,541,608
+2,246,945
+27% +$5.31M 1.11% 28
2025
Q2 		$14.3M Buy
8,294,663
+2,804,864
+51% +$6.98M 0.81% 46
2025
Q1 		$18.3M Buy
+5,489,799
New +$28.3M 0.92% 30
2024
Q1 		– Sell
-1,053,251
Closed -$8.56M – 164
2023
Q4 		$8.56M Buy
+1,053,251
New +$5.51M 0.39% 76

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Invenomic Capital Management's IOVA Position: Q2 2026 in Review

Invenomic Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 83% in Q2 2026, selling an estimated $26.6M and leaving 1,482,595 shares worth $6.17M. The position accounts for 0.37% of the portfolio, ranked #76.

Invenomic Capital Management first reported a position in IOVA in Q4 2023 and has held it in 7 quarters since. The position peaked at $32.6M in Q4 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Invenomic Capital Management held 1,482,595 shares of Iovance Biotherapeutics worth $6.17M as of Q2 2026.
  • Invenomic Capital Management sold 7,012,956 Iovance Biotherapeutics shares in Q2 2026, an estimated $26.6M.
  • Iovance Biotherapeutics made up 0.37% of Invenomic Capital Management's portfolio in Q2 2026, its #76 holding.
  • Invenomic Capital Management first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 7 quarters since.
  • Invenomic Capital Management's Iovance Biotherapeutics position peaked at $32.6M in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.